Eptinezumab Continues Migraine Reduction Past Second Dosing in PROMISE 2
July 2nd 2018In these new study results, patients administered 300 mg eptinezumab reported 8.2 fewer MMDs from baseline—when mean patient MMDs were 16.1 per month. The rate was significantly improved from that of patients administered placebo.
Read More
Canagliflozin Does Not Increase Risk of Amputation, Despite Boxed Warning
June 29th 2018In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.
Read More
Nonfatal Opioid Overdose Greatly Raises Risk of Short-Term Death
June 20th 2018Researchers found nonfatal opioid overdose survivors have a 20-fold greater mortality rate in the months following their incident. However, designated therapies for such patients have been proven to counter that risk.
Read More